Status:
UNKNOWN
The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw
Lead Sponsor:
Barzilai Medical Center
Conditions:
Oral Squamous Cell Carcinoma
Medication Related Osteonecrosis of the Jaw
Eligibility:
All Genders
20-90 years
Brief Summary
Oral squamous cell carcinoma (OSCC) is the most common malignant tumor of the head and neck, and its incidence has increased in recent years. Extensive surgery with neck dissection and chemo/radio/ ta...
Eligibility Criteria
Inclusion
- Patients biopsied with OSCC
- Patients biopsied with oral premalignant lesions
- Patients biopsied with osteonecrosis of the jaw
- healthy age matched patients that visit the oral and maxillofacial clinic for other purposes such as extraction, reactive lesions
Exclusion
- Patients receiving antimicrobial treatment in the previous 3 months
- Patients receiving radiotherapy
- Patients receiving chemo/immunotherapy
Key Trial Info
Start Date :
December 14 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03418454
Start Date
December 14 2017
End Date
December 31 2021
Last Update
January 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barzilai medical Center
Ashkelon, Israel